BEHAVIORAL PHARMACOLOGY OF CHRONIC BENZODIAZEPINE USE
长期使用苯二氮卓类药物的行为药理学
基本信息
- 批准号:3211481
- 负责人:
- 金额:$ 12.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1989
- 资助国家:美国
- 起止时间:1989-04-01 至 1994-05-31
- 项目状态:已结题
- 来源:
- 关键词:albino rat alprazolam behavior modification behavior test benzodiazepines buspirone diazepam drug abuse drug administration rate /duration drug adverse effect drug tolerance drug withdrawal lorazepam midazolam operant conditionings pharmacokinetics psychological reinforcement psychopharmacology tranquilizer
项目摘要
The role of behavioral-environmental factors in the development of
tolerance and drug withdrawal to benzodiazepines (BZs) will be investigated
in six separate experiments with albino rats. An examination of both
contingent and non-contingent components of operant responding are
emphasized as potential modes for behavioral change during the development
of tolerance and withdrawal. Two operant experiments will explore the
development of tolerance and withdrawal produced by 30 days of pre and
postsession exposure to modest doses of two BZs, midazolam (MZ) and
diazepam (DZ), when reinforcement is dependent on the duration of the
responses or the force of responses rather than rate of responding. Since
duration of drug action is an important predictor of drug abuse and of
behavioral tolerance phenomena, one experiment will compare the development
of tolerance as assessed with the multiple FR:FI operant schedule to two
intermediate-duration-of-action BZs, alprazolam (AP) and lorazepam (LP),
which have dissimilar pharmacological profiles. AP is more efficacious
clinically as an anxiolytic and LP is more efficacious as a muscle
relaxant. The importance of duration of BZ activity in the development of
behavioral tolerance and drug withdrawal will be further explored by
manipulation of inter-drug interval in rats exposed to MZ (28 total drug
exposures) as a model for drug "binging". With total cumulative dose being
held constant, three different dosing regimens will be examined:
continuous daily exposure, two days of exposure followed by five days of no
exposure, and four days of exposure followed by three days of no exposure.
Previous data on repetitive exposure to BZs will be extended to examine the
importance of behavioral-environmental factors in repetitive exposure to
two non-BZ anxiolytics, buspirone (BU) and gepirone (GP), which mediate
their effects via 5-HT1A receptors. The final project will evaluate the
importance of chronically experiencing MZ while responding in predicting
long term alterations in sensitivity to BZs and the non-BZ anxiolytic
buspirone (BU).
行为-环境因素在儿童精神分裂症发生发展中的作用
将调查对苯二氮类药物(BZS)的耐药性和停药情况
在六个单独的白化大鼠实验中。对两者的考察
操作型反应的偶然性和非偶然性成分包括
被强调为在发展过程中行为改变的潜在模式
宽容和退缩。两个可操作的实验将探索
30天的耐受性和戒断反应的发展
会后暴露于中等剂量的两种BZ、咪达唑仑(MZ)和
安定(DZ),当加固取决于持续时间时
反应或反应的力量,而不是反应的速度。自.以来
药物作用的持续时间是药物滥用的重要预测指标
行为容忍现象,一项实验将比较
用多个FR:FI手术计划评估的耐受性为2
中效BZS、阿普唑仑(AP)和劳拉西潘(LP),
它们有不同的药理特征。AP更有效
临床上,作为一种抗焦虑药物,LP作为一种肌肉更有效
松弛药。BZ活动持续时间在BZ发展中的重要性
行为耐受性和药物戒断将由
MZ染毒大鼠药物间隔的操纵(共28种药物)
暴露),作为吸毒“狂欢”的典范。总累积剂量为
在保持不变的情况下,将检查三种不同的剂量方案:
每天连续暴露,暴露两天,然后不暴露五天
暴露,暴露四天,然后三天不暴露。
之前关于重复暴露于BZS的数据将扩展到检查
行为环境因素在重复暴露中的重要性
两种非BZ类抗焦虑药物丁螺环酮(BU)和吉培酮(GP)
它们通过5-HT1a受体发挥作用。期末项目将评估
应对时长期体验MZ在预测中的重要性
BZS和非BZ抗焦虑药的长期敏感性变化
丁螺环酮(BU)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARY JEANNE KALLMAN其他文献
MARY JEANNE KALLMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARY JEANNE KALLMAN', 18)}}的其他基金
BEHAVIORAL PHARMACOLOGY OF CHRONIC BENZODIAZEPINE USE
长期使用苯二氮卓类药物的行为药理学
- 批准号:
3211480 - 财政年份:1989
- 资助金额:
$ 12.44万 - 项目类别:
BEHAVIORAL PHARMACOLOGY OF CHRONIC BENZODIAZEPINE USE
长期使用苯二氮卓类药物的行为药理学
- 批准号:
3211482 - 财政年份:1989
- 资助金额:
$ 12.44万 - 项目类别:
相似海外基金
Alprazolam and Simulated Driving Performance: Next Day Effects
阿普唑仑和模拟驾驶表现:次日效应
- 批准号:
9455117 - 财政年份:2017
- 资助金额:
$ 12.44万 - 项目类别:
fMRT-Untersuchung der Effekte von Alprazolam auf die experimentelle Auslösbarkeit von Panikattacken mit Cholezystokinin-Tetrapeptid (CCK-4) bei gesunden Probanden
fMRI 研究阿普唑仑对胆囊收缩素四肽 (CCK-4) 实验诱导健康受试者惊恐发作的影响
- 批准号:
109180591 - 财政年份:2009
- 资助金额:
$ 12.44万 - 项目类别:
Research Grants
Alprazolam Abuse Liability in Post Traumatic Stress Disorder (PTSD)
创伤后应激障碍 (PTSD) 中阿普唑仑滥用的责任
- 批准号:
7257589 - 财政年份:2008
- 资助金额:
$ 12.44万 - 项目类别:
Alprazolam Abuse Liability in Post Traumatic Stress Disorder (PTSD)
创伤后应激障碍 (PTSD) 中阿普唑仑滥用的责任
- 批准号:
7628407 - 财政年份:2008
- 资助金额:
$ 12.44万 - 项目类别:
BEHAVIORAL AND REINFORCING EFFECTS OF ALPRAZOLAM IN MONKEYS
阿普唑仑对猴子的行为和强化作用
- 批准号:
7349547 - 财政年份:2006
- 资助金额:
$ 12.44万 - 项目类别:
NALTREXONE AND ALPRAZOLAM-INDUCED FMRI CHANGES
纳曲酮和阿普唑仑引起的 FMRI 变化
- 批准号:
7379477 - 财政年份:2005
- 资助金额:
$ 12.44万 - 项目类别:
NALTREXONE AND ALPRAZOLAM-INDUCED FMRI CHANGES IN ALCOHOLISM
纳曲酮和阿普唑仑引起的酗酒 FMRI 变化
- 批准号:
7206274 - 财政年份:2004
- 资助金额:
$ 12.44万 - 项目类别:
Naltrexone and Alprazolam-induced fMRI Changes
纳曲酮和阿普唑仑引起的功能磁共振成像变化
- 批准号:
7042200 - 财政年份:2003
- 资助金额:
$ 12.44万 - 项目类别:
Naltrexone and alprazolam-induced fMRI changes
纳曲酮和阿普唑仑引起的功能磁共振成像变化
- 批准号:
6621891 - 财政年份:2002
- 资助金额:
$ 12.44万 - 项目类别:
EFFECTS OF REBOXETINE & NEFAZODONE ON PHARMACOKINETICS OF ALPRAZOLAM
瑞博西汀的作用
- 批准号:
6653451 - 财政年份:2002
- 资助金额:
$ 12.44万 - 项目类别: